$DNAC News
Last published 2y ago
- 2y agoALCEBYNCLINPNST+4Wolf Popper LLP Announces Investigations on Behalf of Investors in Materially Underperforming Special Purpose Acquisition CompaniesGlobeNewswireNEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of investors in the following Special Purpose Acquisition Companies (SPAC). The stock prices of these companies,
- 4y agoDNACPROKRevolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. IIIGlobeNewswireProKidney Class A ordinary shares to begin trading on Nasdaq under the ticker symbol "PROK" on July 12, 2022 ProKidney receives total gross proceeds of approximately $597 million, expected to fund Phase 3 study of REACT™ PIPE is led by a $125 mi
- 4y agoDNACSocial Capital Suvretta Holdings Corp. III Announces Reconvened Extraordinary General Meeting of ShareholdersBusiness WireSocial Capital Suvretta Holdings Corp. III ("SCS") today announced that it will reconvene the Extraordinary General Meeting of its shareholders to vote on the Business Combination Agreement, dated as of January 18, 2022, by and between SCS and ProKidney
- 4y agoDNACProKidney Corroborates the Mechanism of Action of REACT™ with Cell Marker Analysis in Patients with Diabetic Chronic Kidney DiseaseGlobeNewswireWINSTON-SALEM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of end-stage renal disease (ESRD) requir
- 4y agoDNACProKidney Announces Manufacturing Efficiency Initiatives and Supply Chain Streamlining Expected to Reduce REACT™ Manufacturing CostsGlobeNewswireWINSTON-SALEM, N.C., June 15, 2022 (GLOBE NEWSWIRE) -- ProKidney LP ("ProKidney"), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease ("CKD"), today announced an update on manufacturing efficiency and
- 4y agoDNACObserved Safety Profile Supports Bilateral Dosing of ProKidney's REACT™ – 007 UpdateGlobeNewswirePotential for Amplified Therapeutic Effect of REACT™ with Bilateral Kidney Injections Potential to report data from enhanced delivery approach 1Q 2023 WINSTON-SALEM, N.C., June 07, 2022 (GLOBE NEWSWIRE) -- ProKidney LP ("ProKidney"), a leading
- 4y agoDNACProKidney to present at upcoming investor conferencesGlobeNewswireWINSTON-SALEM, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of both end-stage renal disease (ESRD) an
- 4y agoDNACProKidney highlights key registrational program elements supporting advancement of REACT®GlobeNewswireWINSTON-SALEM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of both end-stage renal disease (ESRD) an
- 4y agoDNACProKidney Appoints Libbie Parker McKenzie, MD, FASN as Chief Medical OfficerGlobeNewswireWINSTON-SALEM, N.C., April 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and prevention of both end-stage renal disease (ESRD) and
- 4y agoDNACProKidney and Social Capital Suvretta Holdings Corp. III ("SCS") to Host Analyst and Investor Day on April 28, 2022GlobeNewswireWINSTON-SALEM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney) is a leading Phase 3 clinical-stage cellular therapeutics company with Regenerative Medicine Advanced Therapy (RMAT) Designation that has the goal of delaying chronic kidn
- 4y agoDNACProKidney confirms Phase 3 program for autologous kidney cell therapy REACT®GlobeNewswireWINSTON-SALEM, N.C., April 12, 2022 (GLOBE NEWSWIRE) -- ProKidney LP ("ProKidney"), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease ("CKD"), today announced the updated design for its REACT® Phase
- 4y agoDNACProKidney Appoints Todd C. Girolamo as General CounselGlobeNewswireWINSTON-SALEM, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (CKD) and prevention of end-stage renal disease (ESRD) and need for
- 4y agoDNACProKidney to Present REACT® at 4th Annual CKD SummitGlobeNewswirePresentation to include data on Mechanism of Action, clinical trials to-date and current regulatory status WINSTON-SALEM, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company foc
- 4y agoDNACProKidney Announces Online Publication of Trial Design for Phase II Multicenter Clinical Trial of REACT® Autologous Cell Therapy for Treatment of Chronic Kidney DiseaseGlobeNewswireArticle published online in American Journal of Nephrology; to be included in future print edition WINSTON SALEM, N.C., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ProKidney LP ("ProKidney"), a leading clinical-stage cellular therapeutics company focused on
- 4y agoDNACVHAQZGNXBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Zogenix, Inc. (Nasdaq - ZGNX), Social Capital Suvretta Holdings Corp. III (Nasdaq - DNAC), Viveon Health Acquisition Corp. (NYSE American - VHAQ)PR NewswireBALA CYNWYD, Pa., Jan. 26, 2022 /PRNewswire/ -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky or Marc Ackerman at 855-576-4847. There is no cost or fina
- 4y agoATVIDNACVHAQZGNXMoore Kuehn Encourages ATVI, ZGNX, DNAC, and VHAQ Investors to Contact Law FirmGlobeNewswireNEW YORK, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair t
- 4y agoDNACRPRXRevolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. IIIBusiness WireProKidney offers a first-of-its-kind, patented disease-modifying autologous cell therapy for treatment of chronic kidney disease ("CKD") Lead product candidate, REACT®, has potential to slow, stabilize, and even reverse decline in kidney funct
- 5y agoDNACSocial Capital Suvretta Holdings Corp. III Announces Pricing of Upsized $220,000,000 Initial Public OfferingBusiness WireSocial Capital Suvretta Holdings Corp. III (the "Company") announced today that it has priced its upsized initial public offering of 22,000,000 Class A ordinary shares at $10.00 per share. The Class A ordinary shares will be listed on the Nasdaq Capital